

Visual Fields: A Virtual Reality

Walt Whitley, OD, MBA, FAAO
Eye Care Associates of Nevada

2022 Vision Expo East

1

Disclosures - Walter O. Whitley, OD, MBA, FAAO has received consulting fees, honorarium or research funding from:

- Aerie: Consultant, Speaker
- Alcon: Consultant, Speaker
- Allergan: Consultant
- Astareal: Consultant
- Bausch and Lomb: Consultant
- Bruder: Consultant
- CollaborativeEye: Co-Chief Medical Editor
- Dompe: Consultant
- Eyevance: Consultant, Speaker
- Horizon: Consultant
- Heru: Consultant
- J&J Vision: Consultant, Speaker
- Kala: Consultant, Speaker
- MediPrint Pharma: Consultant
- Novartis: Consultant, Speaker
- Oyster Point: Consultant
- Quidel: Consultant, Speaker
- Review of Optometry: Contributing Editor
- RVL Pharmaceuticals: Consultant, Speaker
- Science Based Health: Consultant, Speaker
- Sun Pharmaceuticals: Consultant, Speaker
- Tarsus Pharmaceuticals: Consultant
- TearLab Corporation: Consultant
- ThermoMEDx: Consultant
- Visus Pharmaceuticals: Consultant

2

The Unmet Clinical Need

Why do we need something new?

Glaucoma is a progressive disease that leads to optic disc cupping and visual field loss due to retinal ganglion cell damage and represents the most common cause of irreversible blindness worldwide.

80 million

Globally living with glaucoma (2020)¹

3 million

In the United States living with glaucoma; 2.7m aged >40 with POAG²




• Unfortunately, it is estimated that half of glaucoma patients remain undiagnosed.³

1. Glaucoma. Statista. (2018). <https://www.statista.com/statistics/269881/global-glaucoma-prevalence/>

2. Prevalence of glaucoma in the United States. (2018). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111111/>

3


The Future of Eye Care




<https://www.mathworks.com/discovery/deep-learning.html>

4

Cataract Suite



5



6


Evaluation of an AI system for the automated detection of glaucoma from stereoscopic optic disc photographs: the European Optic Disc Assessment Study

- Objectives - To evaluate the performance of a deep learning based Artificial Intelligence (AI) software for detection of glaucoma from stereoscopic optic disc photographs, and to compare this performance to the performance of a large cohort of ophthalmologists and optometrists.
- Results
 - Pegasus was able to detect glaucomatous optic neuropathy with an accuracy of 83.4% (95% CI: 77.5–89.2)
 - This is comparable to an average ophthalmologist / optometrist accuracy of 80.5% / 80% respectively (95% CI: 67.2–93.8) / (95% CI: 67–88) on the same images.
 - There was no statistically significant difference between the performance of the deep learning system and ophthalmologists or optometrists.


Rogers, TW, Jaccard, N., Carbonara, F. et al. Eye 2019. DOI:10.1038/s41433-019051903

7

AI and OSD




8



9

Digital Health in Modern Optometry


Incorporating digital health care models can help propel optometrists into the realm of **artificial intelligence** and leverage the latest innovations in **remote monitoring**.



10

Digital health care services for AMD patients

Dedicated remote monitoring programs with advanced, AI-based technologies support Optometrist diagnosis of acute nAMD conversion and monitoring of chronic therapy by Retina Specialists between office visits



11


Home OCT for monitoring chronic therapy of neovascular AMD between office visits



12


Icare Home

A device is intended as an adjunct for monitoring IOP of adult patients (self-use). The HOME tonometer is designed for use at home or on the go.



13

Self-Monitoring Makes a Difference



Arsani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. *J Glaucoma*. 2000;9:134-14

3/2/22

14

14

Where are we Going with Visual Field Technology?

15


Advancements in VF Technology



Liquid Lens Technology



Faster 24-2C



16

At Home VF Testing

- Quick test time improves patient's experience
- Monitors and records patient's progression
- Accurate HFA style report
- Telehealth reimbursement using existing CPT codes




Smart System® VF Headset

17


Objective Visual Field Testing

- FDA 510(K) Cleared
- Tests OU simultaneously in 7 minutes
- Measures the response of the pupils to a stimulus



18

Objective Visual Field Testing



Video Courtesy of Konan Medical

19

NEI: See What I See Virtual Reality Eye Disease Experience

- AMD
- Diabetic retinopathy
- Cataracts
- Glaucoma - <https://youtu.be/cVFzDrmAY78>

20


Artificial
Intelligence
+
Virtual Reality
=
Eye Care's New
Frontier??

21

Virtual Reality is Here!!!

- Visual Field
- Visual Acuity
- Color Vision (D-15) 92283
- Pediatrics Visual Field
- Contrast Sensitivity
- Low Contrast Visual Acuity
- Dark Adaptation 92284
- Many more tests in the works....


22



23

What is the Same?

Correlates strongly with the standard of care, throughout the dynamic range.



24

The Benefits

Light shield blocks the light; testing can be performed in waiting areas and exam lanes.

Threshold testing strategy is statistically significantly faster than the HFA SITA standard.

- 4.3 vs 5 minutes respectively; $P < 0.001$
- 15% gain in pathologic eyes
- 8% gain in healthy eyes

Excellent Reproducibility

- ICC of 0.95 (95% CI 0.86-0.98) in normal eyes
- ICC of 0.80 (95% CI 0.78-0.82) in pathologic eyes



Virtual Personality

The virtual "personality" instructs and monitors your patients, freeing up your clinician/technician during the examination to tend to your growing practice.




25

What tests are available?




26

65yo male with moderate POAG



27


72yo female with POAG



28

Testing Modalities

Document and monitor macular health.



Contrast Sensitivity

- Rolling "E" contrast sensitivity testing.
- Developed in partnership with Bascom Palmer Eye Institute and MacuHealth.
- Moves test out of the exam lane.
- Test performed in full room lighting.


Technician and/or clinician not required to administer exam.

29

Testing Modalities

Coming Soon...

Optimize practice efficiency and the patient experience.



Color Vision Testing

- Ishihara color vision screening AND
- Farnsworth D-15 extended color vision test.
- If patient fails the Ishihara test, the re:Vive Auto Workflow feature automatically moves to a D-15 exam to determine the type of color deficiency presented.
- D-15 extended color vision test is a reimbursable service.
- CPT Code 92283.

Technician and/or clinician not required to administer exam.

30

VR Platform

- Headset
 - Balanced design
 - Disinfectable
 - Comfortable
 - Portable
- Cloud
 - Microsoft Azure
 - Hippa Compliant
 - A.I. Powered
- WebApp
 - Command Center
 - Start/Stop Test
 - Remote Monitor
 - Patient Record



32

31


VR VF Software

Visual Field

- Normal T - 10-2/24-2/30-2 (4min/eye) **(92083)**
- Supra T (Screener) - 10-2/24-2/30-2 (1.5min/Eye) **(92082)**
- Pediatric Normal T - 10-2/24-2 (4-5min/eye) **(92083)**
- SupraFast (45 sec/eye Screener) **(92082)**
- Esterman Testing

32

Reports are easy to read and easily exported to your EMR




33

33

[illegible]

34

Color Vision




35

Back to Visual Fields.....


36

Indications for VF

- Glaucoma: 24-2 vs. 30-2
 - Few peripheral defects were seen in new/early glaucoma*





- Retina
 - Hydroxychloroquine maculopathy
 - Detachments
 - Macular degeneration



37

Indications

- Neuro
 - Strokes
 - Masses
 - Optic neuropathies
 - Pseudotumor cerebri
- Freedoms and Limitations
 - DMV testing
 - Disability Requirements



38

Setting Up For Success

- Attitude adjustment – What? Why? Where? How?
- Lens alignment
- Patient comfort and instruction

39

Lens Correction

- 1 diopter uncorrected = reduction in 1 decibel of sensitivity
- <2 diopters of astigmatism can use spherical equivalent
 - Less lenses decreases the chances of lens rim defects
- Lens should be as close to the eye as possible
- Humphrey system makes age-adjusted correction for presbyopic patients
- Consistency

40

Which Test do you Choose?

- Strategies
 - 10-2
 - 24-2
 - 30-2
 - 60-4
 - Leicester
 - Esterman

41

10-2

- Indications:
 - Plaquenil testing
 - Retinal conditions
 - Glaucoma
 - Severe AND mild*
- Tests: 10 degrees from central fixation
- 68 locations
- Points are 2 degrees apart
- Time:

42

24-2 SITA: Swedish Interactive Thresholding Algorithm

- Indications: glaucoma
- Tests: 24 degrees from central fixation
- 54 locations
- Points 6 degrees apart
- Time: 3-7 minutes per eye
- Very similar to 30-2
 - Excludes superior, inferior, and temporal edge points
 - Keeps nasal

43

SITA Standard

44

30-2

- Indications:
 - Neuro cases
 - glaucoma
- Tests: 30 degrees from central fixation
- 76 locations
- Points 6 degrees apart
- Time: 5.5-10 minutes per eye
- Pros:
 - Potentially see defects sooner
- Cons:
 - Longer and more chance for artifacts

45

It's all in the details...

STIM size

- 1 through 5 available
- III: standard Goldmann
 - 0.43 degree stimulus
- V: advanced loss
 - 1.72 degree stimulus
- Optic nerve size: 5H x 7H degrees

Background Illumination

- 10 Cd/m² white background
- Goldmann bowl standard
- Similar to photopic environment

46

It's all in the details...

Threshold vs Suprathreshold

- Threshold: measuring the dimmest at each point
- Suprathreshold: starting brighter to determine loss at any point
 - Pros: easier
 - Cons: not as sensitive to subtle defects

Duration

- 200 milliseconds
- Shorter than a voluntary eye movement

47

SITA-Fast

- Indications:
 - Experienced glaucoma test takers
 - Neuro tests without other pathology
- Duration
 - 10-2:
 - 24-2: 2-5 minutes/eye
 - 30-2: 3-7 minutes/eye
- Pros:
 - Faster
- Cons:
 - Beginning stimulus is dimmer

48

A New SITA Perimetric Threshold Testing Algorithm: Construction and a Multicenter Clinical Study

ANDERS HEIL, VINCENT MICHAEL PATELLA, LURE X. CHONG, AND THANE CHRISTOPHER K. LEUNG, ANJA TUULONEN, GARY C. LEE, THOMAS CAULAN, AND BOB BENGTSSON

PURPOSE: To describe a new time-saving threshold visual field-testing strategy—Swedish Interactive Thresholding Algorithm (SITA) Fast, which is intended to replace SITA Fast—and to report on a clinical evaluation of this new strategy.

QJ0404040 2019;198:154-165. © 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

30.4% shorter than SITA Fast
53.5% shorter than SITA Standard

49

Navigating the Printout

- Patient name
- Reliability
- Strategy
- Patient information
- Raw threshold data
- Grayscale map
- Total Deviation numerical map
- Pattern Deviation map
- Total Deviation Probability map
- Pattern Deviation Probability map
- Gaze Tracker

50

Reliability

- **Fixation Losses**
 - Occasionally checks blind spot
 - Detects fixation shifts of at least 3 degrees
 - >20% = unreliable
- **False POS Errors**
 - Pressing button when stimulus not presented
 - >15% = unreliable
- **False NEG Errors**
 - Did not press button in response to stimulus
 - Presented in locations where threshold is normal

51

Threshold

- Bright to dim to determine threshold
- 51 decibel range
- 0= max brightness
- 51=min brightness
- Normal threshold ~ 40 dB

52

Grayscale Map

- Excellent tool for patient education and understanding
- Limited valuable info
 - Can show artifacts

53


Total Deviation

- Compares age
- Numerical Map
- Probability Map
- Central sensitivity is less variable than the periphery
- < 5%, 2%, 1%, and 0.5% of study subjects of the same age

54

Pattern Deviation


- Remaining defect after general depression or elevation factored out
- Decreases appearance of artifacts



55

Gaze Tracker


- Tracks the center of the pupil
- Measures gaze when each stimulus is presented
- Accurate to 1 degree
- Uptick = gaze error
 - Higher = worse deviation
- Downtick = blink



56

Navigating the Printout

- Glaucoma Hemifield
 - Compares 5 sup vs inf zones
 - Outside Normal= at least one zone is worse than 1%
 - Borderline= at least one zone is worse than 3%
 - General Reduction of Sensitivity= high TD like cataract
 - Specificity is 84% when Borderline findings are outside normal limits



57

Global Indices


- VFI: Visual Field Index
 - Reflects changes to ganglion cell loss
 - 100%= full
 - 0%= blind fields
- MD: Mean Deviation
 - Weighted average of TD map
 - 0dB= normal
 - -35dB= nearing blindness
- PSD: Pattern Standard Deviation
 - Measures amount of localized defects
 - Hill type pattern
 - 0= normal or total blindness



58

Glaucoma

- Defects
 - Nasal step
 - Paracentral
 - Temporal wedge
 - Altitudinal
 - Arcuate
 - Total Constriction
 - W/ or w/out central island remaining
- Same descriptions for 24-2 and 10-2



59

Case Presentation

- CC: vision cloudy OS>OD
- HPI: 68 yo WM presents for cataract evaluation with h/o controlled moderate OAG OS>OD
- Current meds: Levobunolol QD OU, Travataprost qhs OU, Optive
- POHx: SLT OU 2007
- FamHx: mother with glaucoma

60

Case Presentation

- BCVA : 20/40 OD, 20/50 OS
- Present Rx: OD -0.50+1.00 x 075 OS -1.00 +0.75 x 110
- Keratometry: OD 43.67/44.00 x 055 OS 43.25/44.37 x 85
- IOP: OD 14, OS 14 (GAT)
- CCT: OD 527, OS 512
- CH: 9.4/9.6
- Tmax: OD 20; OS 24
- Gonioscopy: OU open to scleral spur
- SLE 2+ NS OU


61

Case Presentation

- Dilated Fundus Exam:
- Optic Nerve:
CDR OD: vert 0.55 horiz 0.5
(thin rim infer/sup)
CDR OS: vert 0.7 horiz 0.65
- Macula: OU Flat
- Vessels: WNL
- Periphery: WNL



62



63

Case Presentation

- Diagnosis: VS Cataract OU, Controlled Glaucoma
- Type of Glaucoma: open angle glaucoma
 - Stage of Glaucoma: **Severe OS>Moderate OD**
 - What is the Tmax? 20/24
 - What is the target pressure? **Low teens OU**
 - Is current treatment adequate? **Yes**

64

Case 2: 84 yo AA Female

- CC: presents for 3 month IOP check and 24-2 OU for bilateral severe POAG
 - Pt reports no change to vision
- Drops:
 - Dorzolamide BID OU
 - Brimonidine/timolol TID OU
 - Latanoprost QHS OU
- s/p SLT OD 2012
- Target IOP: 12 mm Hg or below OU
- Other Ocular Conditions
 - OIS OU
 - Dry Eye


65

Entrance Testing and Ocular Exam

- BCVA
 - OD: 20/40-1
 - OS: 20/25
- Pupils: round, reactive, equal
- EOMS: full
- IOP
 - OD: 14 mmHg
 - OS: 12 mmHg
- Gonio: SS 360, 2+ pigment OU
- Adnexa, lids, conj: clear
- Cornea: trace SPK OU
- Lens: PCIOL OU
- Undilated Nerves
 - OD: 0.9 c/d
 - OS: 0.9 c/d


66

Optic Nerves, stable compared to last several




67

Visual Field




68

Let's Compare to 2019 - OD



69

Let's Compare to 2019 - OS



70

Assessment and Plan

- H40.1133 POAG, bilateral, severe
 - Elevated IOP OD and VF progression OS
 - NEW Target for OS 10 mmHg
 - Switch latanoprost QHS to latanoprost/netarsudil QHS OU
 - Continue:
 - Dorzolamide BID OU
 - Brimonidine/timolol TID OU
- RTC 4-6 weeks for IOP check and 10-2 VF

71

How do we Determine Progression?

- Interpreting decibels
- Using the machine
 - Guided Progression Analysis

72


Interpreting Decibels

- Try to compare reliable fields
- New Defects
 - 10 dB change per point
 - At least 2 points with 5dB change in central 10 degrees
 - At least 3 points with 5dB change outside
- Previous Defects
 - 15 dB change per point
 - Any point in the central 10 degrees with a 10 dB change
 - 3 or more points outside the central 10 degrees with a 10dB change on 2 fields or a 5dB on 3 fields

73

Guided Progression Analysis


- Two baseline fields
- VFI Trend Graph
- Current Field
- GPA Alert



74

GPA - VFI


- Gives a prediction based on the trend
 - Must have 5 fields
- Fields with >15% FP are not counted
- Estimate rate of progression
- Slope
 - Not significant= stable
 - Significant at $p < 0.1\%$ = progression



75

GPA - Alert

- Triangles
 - Darken as defects are repeated
 - Numbers indicate statistical significance
- Alert
 - No Progression detected
 - Possible Progression
 - Likely Progression



76

Case 2: 66 yo AA Male


- CC: 4m IOP check/24-2/DFE for POAG moderate OD, mild OS
 - Pt reports no changes to vision
- Drops:
 - Dorzolamide-timolol QAM OU
 - Latanoprost QHS OU
- s/p SLT OD 04/2020
- Target IOP
 - OD: mid-teens
 - OS: teens
- Tmax
 - OD: 31
 - OS: 33

77


Entrance Test and Ocular Exam

- BCVA
 - OD: 20/20
 - OS: 20/25
- Pupils: round, reactive, equal
- EOMS: full
- IOP:
 - 15mmHg OD
 - 14mmHg OS
- Anterior Segment
 - Lens: 2+ NS OD/OS


78




79




80




81



82



83



84

Dilated Exam




85

Assessment and Plan


- H40.1112 POAG Moderate
 - Discussed SLT vs improving compliance and increasing drops
 - Pt elects the former
 - Increase dorzolamide-timolol to BID, continue latanoprost QHS OU
- RTC in 4-6 wks IOP and compliance check

86

High FP 2019





Improved Field 6 Months Later



87

Comparing TD>PD


- Main cause:
 - Ant seg path
 - cataracts
- Or s/p ! →
- Miosis
- Uncorrected rx



88

COVID Ruins Everything

- Mask defect
- Improved by taping upper edge of mask




Alan Robin MD

89

Clover leaf


- Inattention
 - Attention decreased
- Reversed
 - Attention increased




90

Field Interference

Lens Rim



Lid Defect



91

Visual Field Coding and Billing Considerations

92

AOA Clinical Practice guidelines

Frequency and Composition of Evaluation				and Management Visits for Open Angle Glaucoma			
Type of Patient, Stage of Disease	Examination Frequency	Testimony	Guidance	ONH/NL Assessment	Swampert, ON, NLP, PPA Documentation	CHL ²	Management Plan
New glaucoma patient or new glaucoma suspect	Weekly or biweekly to achieve target pressure	Multiple readings may be needed to establish baseline	Standard classification and documentation of initial visit	Discuss early, early documentation at initial visit	As part of initial glaucoma evaluation	Discuss to establish baseline	Formulate problem list with treatment plan
Glaucoma suspect	6-12 months, depending on level of risk	Multiple readings may be needed to establish baseline	Annually	Discuss every year or	Annual	Annual	Review
Stable, mild	3-6 months	Every visit	Annually	Discuss every year or	Annual	Annual	Review
Stable, moderate	2-4 months	Every visit	Annually	Discuss every year or	Annual	Annual	Review
Stable, severe	1-3 months	Every visit	Annually	Discuss every year or	Annual	Annual	Review
Unstable, ROP poorly controlled, ON or VF progressing	Weekly or biweekly until stability is established	Every visit	Initial visit and each time other clinical findings warrant measurement	Discuss at initial visit and each time other clinical findings warrant measurement	Annual or each time ON or NLP changes	4-12 months, depending on prior data	Formulate new plan and schedule
Stability recently established	1-3 months	Every visit, establish baseline	Depends on severity of the disease	Discuss every year	Annual or each time ON or NLP changes	4-6 months, depending on severity of the disease	Review

¹Visual evoked responses, visual evoked responses, and optical coherence tomography are of limited utility in glaucoma suspect patients and should not be used to monitor disease risk or to guide treatment. They may be performed up to 3 times per year for patients with variable test-to-test control and/or

<http://www.aoa.org/documents/ophthalmology/CPC-9.pdf>

93

AAO Preferred Practice Patterns

CONSENSUS-BASED GUIDELINES FOR FOLLOW-UP GLAUCOMA STATUS			
Target IOP Achieved	Progression of Damage	Duration of Control (mos)	Approximate Follow-up Interval (mos)*
Yes	No	≤6	6
Yes	No	>6	6-12
Yes	Yes	NA	1-2
No	Yes	NA	1-2
No	No	NA	3-6

IOP = intraocular pressure; NA = not applicable

* Patients with more advanced damage or greater lifetime risk from primary open-angle glaucoma may require more frequent evaluations. These intervals are the maximum recommended time between evaluations.

- VF evaluation should be performed at least yearly
- Rapid visual field progression may be detected earlier by performing three visual fields per year during the first 2 years.

<https://www.aoa.org/preferred-practice-pattern/primary-open-angle-glaucoma-ppp>

94

Glaucoma Staging Based on VF - AAO

Mild or Early Stage Glaucoma

ICD-10 7th digit "1"

- Optic nerve abnormalities consistent with glaucoma
- but NO visual field abnormalities on at least

Moderate Stage Glaucoma


ICD-10 7th digit "2"

- Optic nerve abnormalities consistent with glaucoma
- AND glaucomatous visual field abnormalities in ONE hemifield and

Advanced, Late, Severe Stage

ICD-10 7th digit "3"

- NOT within 5 degrees of fixation (not involvement of spots nearest fixation)
- Optic nerve abnormalities consistent with glaucoma
- AND glaucomatous visual field abnormalities in BOTH hemifields
- AND/OR loss within 5 degrees of fixation in at least one hemifield



95

ICD-10 and Glaucoma

- If both eyes have same stage, use the bilateral ICD-10 code
- If eyes are at different stages, code each eye individually, list more severe eye first on claim
- Indeterminate - Used when stage cannot be clinically determined
- Unspecified - Used when there isn't any documentation regarding glaucoma stage

Slide Courtesy of Tom Cheezum, OD, CFC, CPOC

96

Important Considerations for Test

- 1) Medically Necessary?
- 2) Is the test reasonable – frequency of testing?
- 3) Is the test appropriate – is it going to provide the best information for the patient's problem (OCT vs. Photos)?

Slide Courtesy of Tom Cheezum, OD, CPC, CPDC

97

Testing and I&Rs

Sequence

1. Dr. sees pt and determines need for further diagnostic testing
2. Dr. determines the most appropriate test(s) for problem
3. Dr. enters order in pt record for same day or future date testing. Order documents medical necessity for testing
4. Testing done.
5. Doctor does Interpretation and Report
6. **Standing orders do not override this sequence**

I&R

1. Test done, patient reliability
2. Test interpretation, diagnosis
3. Comparative analysis, if appropriate
4. Management, orders for future testing
5. Dr. Signature

Slide Courtesy of Tom Cheezum, OD, CPC, CPDC

98

Testing Frequency Guidelines

- Often included in NCD/LCDs and depend on staging of disease
- Visual Fields
 - 1x/yr – borderline or controlled
 - 2x/yr – for uncontrolled
 - 3x/yr – for rapidly progressing
- OCT (92133)
 - 1x/yr – suspect or mild
 - 1-2x/yr of VF or OCT - moderate

Slide Courtesy of Tom Cheezum, OD, CPC, CPDC

99

Important Testing Considerations

- “If both SCODI and visual field tests are used, only one of each test would be considered medically necessary, as these tests provide duplicative information”
- “Advanced” Glaucoma - “SCODI is not considered medically reasonable and necessary visual fields are more likely to detect small changes than SCODI”
- 2021 Medicare LCD document for SCODI

Slide Courtesy of Tom Cheezum, OD, CPC, CPDC

100

Conclusion

- Fields are more difficult to interpret than an objective test
- Describing fields and understanding the field maps aids in management
- Remember the Landmark Studies: AGIS, CIGTS
- Frequency based on medical necessity

101

Thank You!!!

wowhitley@eyecareassociatesnv.com

102